Suppr超能文献

结膜原发性获得性黑变病:311只眼的经验

Primary acquired melanosis of the conjunctiva: experience with 311 eyes.

作者信息

Shields Jerry A, Shields Carol L, Mashayekhi Arman, Marr Brian P, Benavides Raquel, Thangappan Archana, Phan Laura, Eagle Ralph C

机构信息

Oncology Service, Wills Eye Institute, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

出版信息

Trans Am Ophthalmol Soc. 2007;105:61-71; discussion 71-2.

Abstract

PURPOSE

To evaluate clinical features and risks for transformation of conjunctival primary acquired melanosis (PAM) into melanoma.

METHODS

Retrospective chart review and Kaplan-Meier estimates of times to PAM enlargement, recurrence, and transformation into melanoma.

MAIN OUTCOME MEASURES

PAM enlargement, recurrence, and transformation into melanoma.

RESULTS

The mean patient age at diagnosis of PAM was 56 years; 62% were female and 96% Caucasian. The conjunctival quadrant(s) affected by PAM and its extent in clock hours were recorded. Initial management included observation in 62%, biopsy combined with cryotherapy in 34%, and other methods in 4%. Of PAM that was observed, Kaplan-Meier estimates at 10 years revealed PAM enlargement in 35% and transformation into melanoma in 12%. Of those that underwent incisional or excisional biopsy, 10-year estimates of PAM recurrence and transformation into melanoma were 58% and 11%, respectively. Progression to melanoma occurred in 0% of PAM without atypia, 0% of PAM with mild atypia, and 13% of PAM with severe atypia. Multivariable analysis revealed that the most significant factor for both PAM recurrence and progression to melanoma was extent of PAM in clock hours.

CONCLUSION

PAM without atypia or with mild atypia shows 0% progression into melanoma, whereas PAM with severe atypia shows progression into melanoma in 13%. The greater the extent of PAM in clock hours, the greater the risk for transformation into melanoma.

摘要

目的

评估结膜原发性获得性黑色素沉着症(PAM)转变为黑色素瘤的临床特征及风险。

方法

回顾性病历审查,并采用Kaplan-Meier法估计PAM增大、复发及转变为黑色素瘤的时间。

主要观察指标

PAM增大、复发及转变为黑色素瘤。

结果

PAM诊断时患者的平均年龄为56岁;62%为女性,96%为白种人。记录了受PAM影响的结膜象限及其在钟点数上的范围。初始治疗包括62%的观察、34%的活检联合冷冻治疗以及4%的其他方法。对于接受观察的PAM,10年的Kaplan-Meier估计显示35%的PAM增大,12%转变为黑色素瘤。对于接受切开活检或切除活检的患者,PAM复发及转变为黑色素瘤的10年估计分别为58%和11%。无异型性的PAM进展为黑色素瘤的比例为0%,轻度异型性的PAM为0%,重度异型性的PAM为13%。多变量分析显示,PAM复发及进展为黑色素瘤的最显著因素是PAM在钟点数上的范围。

结论

无异型性或轻度异型性的PAM进展为黑色素瘤的比例为0%,而重度异型性的PAM进展为黑色素瘤的比例为13%。PAM在钟点数上的范围越大,转变为黑色素瘤的风险越高。

相似文献

1
Primary acquired melanosis of the conjunctiva: experience with 311 eyes.
Trans Am Ophthalmol Soc. 2007;105:61-71; discussion 71-2.
2
Primary acquired melanosis of the conjunctiva: risks for progression to melanoma in 311 eyes. The 2006 Lorenz E. Zimmerman lecture.
Ophthalmology. 2008 Mar;115(3):511-519.e2. doi: 10.1016/j.ophtha.2007.07.003. Epub 2007 Sep 20.
3
Primary acquired melanosis/melanoma: utility of conjunctival map biopsy.
Br J Ophthalmol. 2022 May;106(5):605-609. doi: 10.1136/bjophthalmol-2020-317772. Epub 2020 Dec 18.
4
Primary acquired melanosis of the conjunctiva.
Optometry. 2006 May;77(5):223-8. doi: 10.1016/j.optm.2006.02.007.
6
Primary acquired melanosis of the conjunctiva.
Hum Pathol. 1985 Feb;16(2):129-35. doi: 10.1016/s0046-8177(85)80061-7.
7
Case of Rapidly Expanding Conjunctival Malignant Melanoma Initially from Primary Acquired Melanosis Diagnosed 14 Years Earlier.
Int Med Case Rep J. 2021 May 28;14:361-364. doi: 10.2147/IMCRJ.S310702. eCollection 2021.
10
Clinical and Histopathological Features of Corneal Primary Acquired Melanosis and Melanoma.
Ocul Oncol Pathol. 2021 Mar;7(2):103-107. doi: 10.1159/000511596. Epub 2021 Jan 21.

引用本文的文献

1
Corneally displaced conjunctival Melanoma: Rare presentations of recurrent melanoma.
Am J Ophthalmol Case Rep. 2025 Jul 15;39:102387. doi: 10.1016/j.ajoc.2025.102387. eCollection 2025 Sep.
2
Subepithelial Lesions of the Ocular Surface: A Review.
Curr Ophthalmol Rep. 2025;13(1):8. doi: 10.1007/s40135-025-00335-8. Epub 2025 Jun 21.
3
Emerging Techniques in the Treatment of Conjunctival Melanoma.
Curr Ophthalmol Rep. 2025;13(1):7. doi: 10.1007/s40135-025-00334-9. Epub 2025 Jun 13.
4
Netarsudil-associated conjunctival pigmentation.
Am J Ophthalmol Case Rep. 2025 Mar 25;38:102311. doi: 10.1016/j.ajoc.2025.102311. eCollection 2025 Jun.
6
Biological characteristics and clinical management of uveal and conjunctival melanoma.
Oncol Res. 2024 Jul 17;32(8):1265-1285. doi: 10.32604/or.2024.048437. eCollection 2024.
7
Malignant Transformation of Reese's Melanosis: A Case of Conjunctival Melanoma and Related Therapeutic Modalities.
Cureus. 2024 Jun 13;16(6):e62331. doi: 10.7759/cureus.62331. eCollection 2024 Jun.
8
Conjunctival Melanoma: A Case Presentation.
Iran J Pathol. 2023;18(4):488-491. doi: 10.30699/IJP.2023.557981.2941. Epub 2023 Oct 15.
9
Worldwide Incidence of Ocular Melanoma and Correlation With Pigmentation-Related Risk Factors.
Invest Ophthalmol Vis Sci. 2023 Oct 3;64(13):45. doi: 10.1167/iovs.64.13.45.
10
Genetic Aspects of Conjunctival Melanoma: A Review.
Genes (Basel). 2023 Aug 23;14(9):1668. doi: 10.3390/genes14091668.

本文引用的文献

3
Clinical survey of 1643 melanocytic and nonmelanocytic conjunctival tumors.
Ophthalmology. 2004 Sep;111(9):1747-54. doi: 10.1016/j.ophtha.2004.02.013.
4
Tumors of the conjunctiva and cornea.
Surv Ophthalmol. 2004 Jan-Feb;49(1):3-24. doi: 10.1016/j.survophthal.2003.10.008.
5
Topical mitomycin treatment for primary acquired melanosis of the conjunctiva.
Ophthalmic Plast Reconstr Surg. 2003 Mar;19(2):149-51. doi: 10.1097/01.IOP.0000055826.30486.CC.
8
Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients.
Arch Ophthalmol. 2000 Nov;118(11):1497-507. doi: 10.1001/archopht.118.11.1497.
10
Conjunctival amelanotic malignant melanoma arising in primary acquired melanosis sine pigmento.
Ophthalmology. 1998 Jan;105(1):191-4. doi: 10.1016/s0161-6420(98)92156-x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验